The mouse monoclonal antibody 2H7 recognizes an extracellular epitope on CD20 (B1, Bp35), a 33-37 kDa non-glycosylated membrane receptor with four transmembrane domains, expressed on pre-B lymphocytes, resting and activated B cells (not plasma cells), follicular dendritic cells, and at low levels on peripheral blood T lymphocytes.
MS4A1
Reaktivität: Human
FACS
Wirt: Maus
Monoclonal
LT20
unconjugated
Applikationshinweise
Flow cytometry: Recommended dilution: 1-4 μg/mL.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1 mg/mL
Buffer
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Do not freeze.
Lagerung
4 °C
Informationen zur Lagerung
Store at 2-8°C. Do not freeze.
Hayden-Ledbetter, Cerveny, Espling, Brady, Grosmaire, Tan, Bader, Slater, Nilsson, Barone, Simon, Bradley, Thompson, Wahl, Ledbetter: "CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 15, Issue 8, pp. 2739-46, (2009) (PubMed).
Diehl, Schmidlin, Nagasawa, van Haren, Kwakkenbos, Yasuda, Beaumont, Scheeren, Spits: "STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 180, Issue 7, pp. 4805-15, (2008) (PubMed).
Polyak, Ayer, Szczepek, Deans: "A cholesterol-dependent CD20 epitope detected by the FMC7 antibody." in: Leukemia, Vol. 17, Issue 7, pp. 1384-9, (2003) (PubMed).
Chan, Hughes, French, Tutt, Walshe, Teeling, Glennie, Cragg: "CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts." in: Cancer research, Vol. 63, Issue 17, pp. 5480-9, (2003) (PubMed).
Rose, Smith, Maloney: "Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects." in: Blood, Vol. 100, Issue 5, pp. 1765-73, (2002) (PubMed).
Deans, Robbins, Polyak, Savage: "Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment." in: The Journal of biological chemistry, Vol. 273, Issue 1, pp. 344-8, (1998) (PubMed).
Deans, Kalt, Ledbetter, Schieven, Bolen, Johnson: "Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20." in: The Journal of biological chemistry, Vol. 270, Issue 38, pp. 22632-8, (1995) (PubMed).
Target
CD20 (MS4A1)
(Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1))
MS4A1,CD20 is a cell surface 33-37 (depending on the degree of phosphorylation) kDa non-glycosylated surface phosphoprotein expressed on mature and most malignant B cells, but not stem cells or plasma cells (low number of the CD20 has been also detected on a subpopulation of T lymphocytes and it can be expressed on follicular dendritic cells). Its expression on B cells is synchronous with the expression of surface IgM. CD20 regulates transmembrane calcium conductance (probably functioning as a component of store-operated calcium channel), cell cycle progression and B-cell proliferation. It is associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change and/or BCR (B cell antigen receptor) aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following mAb treatment.,B1, S7, MS4A, Bp35, CVID5, LEU-16